Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 22 |
| List of Tables | 20 | 3 |
| List of Figures | 23 | 1 |
| Introduction | 24 | 1 |
| Global Markets Direct Report Coverage | 24 | 1 |
| Renal Cell Carcinoma Overview | 25 | 1 |
| Therapeutics Development | 26 | 2 |
| Pipeline Products for Renal Cell Carcinoma Overview | 26 | 1 |
| Pipeline Products for Renal Cell Carcinoma Comparative Analysis | 27 | 1 |
| Renal Cell Carcinoma Therapeutics under Development by Companies | 28 | 7 |
| Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes | 35 | 1 |
| Renal Cell Carcinoma Pipeline Products Glance | 36 | 4 |
| Late Stage Products | 36 | 1 |
| Clinical Stage Products | 37 | 1 |
| Early Stage Products | 38 | 1 |
| Unknown Stage Products | 39 | 1 |
| Renal Cell Carcinoma Products under Development by Companies | 40 | 11 |
| Renal Cell Carcinoma Products under Investigation by Universities/Institutes | 51 | 1 |
| Renal Cell Carcinoma Companies Involved in Therapeutics Development | 52 | 95 |
| AbbVie Inc | 52 | 1 |
| Acceleron Pharma, Inc. | 53 | 1 |
| Advenchen Laboratories, LLC | 54 | 1 |
| Altor BioScience Corporation | 55 | 1 |
| Ambrx, Inc. | 56 | 1 |
| Amgen Inc. | 57 | 1 |
| Ampio Pharmaceuticals, Inc. | 58 | 1 |
| Apac Biotech Pvt Ltd | 59 | 1 |
| arGEN-X BV | 60 | 1 |
| Argos Therapeutics, Inc. | 61 | 1 |
| ARMO Biosciences, Inc. | 62 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 63 | 1 |
| Astellas Pharma Inc. | 64 | 1 |
| Bayer AG | 65 | 1 |
| Bio-Cancer Treatment International Limited | 66 | 1 |
| BIOCAD | 67 | 1 |
| Bionomics Limited | 68 | 1 |
| Bionovis SA | 69 | 1 |
| Boehringer Ingelheim GmbH | 70 | 1 |
| Boston Biomedical, Inc. | 71 | 1 |
| Bristol-Myers Squibb Company | 72 | 1 |
| Calithera Biosciences, Inc. | 73 | 1 |
| Cellceutix Corporation | 74 | 1 |
| Celldex Therapeutics, Inc. | 75 | 1 |
| Chipscreen Biosciences Ltd | 76 | 1 |
| Cytune Pharma SAS | 77 | 1 |
| Dr. Reddy's Laboratories Limited | 78 | 1 |
| EirGenix Inc. | 79 | 1 |
| Eisai Co., Ltd. | 80 | 1 |
| Eli Lilly and Company | 81 | 1 |
| Exelixis, Inc. | 82 | 1 |
| F. Hoffmann-La Roche Ltd. | 83 | 1 |
| Five Prime Therapeutics Inc | 84 | 1 |
| Gene Techno Science Co., Ltd. | 85 | 1 |
| Genor BioPharma Co Ltd | 86 | 1 |
| GlaxoSmithKline Plc | 87 | 1 |
| Hemispherx Biopharma, Inc. | 88 | 1 |
| Horizon Pharma Plc | 89 | 1 |
| Hutchison MediPharma Limited | 90 | 1 |
| Immatics Biotechnologies GmbH | 91 | 1 |
| Immune Design Corp. | 92 | 1 |
| Immunicum AB | 93 | 1 |
| ImmunoGen, Inc. | 94 | 1 |
| Immunomedics, Inc. | 95 | 1 |
| Incuron, LLC | 96 | 1 |
| Incyte Corporation | 97 | 1 |
| Inspyr Therapeutics Inc | 98 | 1 |
| Johnson &Johnson | 99 | 1 |
| KAHR medical Ltd. | 100 | 1 |
| Karyopharm Therapeutics, Inc. | 101 | 1 |
| KineMed, Inc. | 102 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 103 | 1 |
| Lead Discovery Center GmbH | 104 | 1 |
| Mabion SA | 105 | 1 |
| MacroGenics, Inc. | 106 | 1 |
| MedImmune LLC | 107 | 1 |
| Medivation, Inc. | 108 | 1 |
| Merck &Co., Inc. | 109 | 1 |
| Merck KGaA | 110 | 1 |
| Millennium Pharmaceuticals Inc | 111 | 1 |
| Molecular Partners AG | 112 | 1 |
| Mologen AG | 113 | 1 |
| Monopar Therapeutics LLC | 114 | 1 |
| Mycenax Biotech Inc. | 115 | 1 |
| Nektar Therapeutics | 116 | 1 |
| NewLink Genetics Corporation | 117 | 1 |
| Novartis AG | 118 | 1 |
| NovaTarg Therapeutics, Inc | 119 | 1 |
| Omeros Corporation | 120 | 1 |
| Oncobiologics, Inc. | 121 | 1 |
| OncoMax | 122 | 1 |
| Ono Pharmaceutical Co., Ltd. | 123 | 1 |
| Peloton Therapeutics, Inc. | 124 | 1 |
| Pfizer Inc. | 125 | 1 |
| Pharmacyclics Inc | 126 | 1 |
| Prima BioMed Ltd. | 127 | 1 |
| PsiOxus Therapeutics Limited | 128 | 1 |
| Rexahn Pharmaceuticals, Inc. | 129 | 1 |
| Richter Gedeon Nyrt. | 130 | 1 |
| Sevion Therapeutics, Inc. | 131 | 1 |
| Sillajen Biotherapeutics | 132 | 1 |
| Sorrento Therapeutics Inc | 133 | 1 |
| Sumitomo Dainippon Pharma Co Ltd | 134 | 1 |
| Syndax Pharmaceuticals Inc | 135 | 1 |
| Taiwan Liposome Company, Ltd. | 136 | 1 |
| Takeda Pharmaceutical Company Limited | 137 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 138 | 1 |
| TC BioPharm Limited | 139 | 1 |
| Theravectys SA | 140 | 1 |
| Tocagen Inc. | 141 | 1 |
| TRACON Pharmaceuticals Inc | 142 | 1 |
| TVAX Biomedical, Inc. | 143 | 1 |
| Tyrogenex, Inc. | 144 | 1 |
| Vascular Biogenics Ltd. | 145 | 1 |
| X4 Pharmaceuticals, Inc. | 146 | 1 |
| Renal Cell Carcinoma Therapeutics Assessment | 147 | 32 |
| Assessment by Monotherapy Products | 147 | 1 |
| Assessment by Combination Products | 148 | 1 |
| Assessment by Target | 149 | 13 |
| Assessment by Mechanism of Action | 162 | 13 |
| Assessment by Route of Administration | 175 | 2 |
| Assessment by Molecule Type | 177 | 2 |
| Drug Profiles | 179 | 576 |
| 1R-2b Drug Profile | 179 | 1 |
| abexinostat hydrochloride Drug Profile | 180 | 2 |
| AGS-16C3F Drug Profile | 182 | 1 |
| AL-2846 Drug Profile | 183 | 1 |
| AL-3818 Drug Profile | 184 | 2 |
| AL-8326 Drug Profile | 186 | 1 |
| alpelisib Drug Profile | 187 | 3 |
| ALT-803 Drug Profile | 190 | 3 |
| AM-0010 Drug Profile | 193 | 3 |
| amcasertib Drug Profile | 196 | 2 |
| apatinib Drug Profile | 198 | 3 |
| Apceden Drug Profile | 201 | 1 |
| APVAC-1 Drug Profile | 202 | 2 |
| ARC-HIF2 Drug Profile | 204 | 1 |
| ARGX-110 Drug Profile | 205 | 4 |
| atezolizumab Drug Profile | 209 | 14 |
| avelumab Drug Profile | 223 | 6 |
| axitinib Drug Profile | 229 | 6 |
| BC-2059 Drug Profile | 235 | 1 |
| BCT-100 Drug Profile | 236 | 2 |
| bevacizumab Drug Profile | 238 | 9 |
| bevacizumab biosimilar Drug Profile | 247 | 2 |
| bevacizumab biosimilar Drug Profile | 249 | 1 |
| bevacizumab biosimilar Drug Profile | 250 | 1 |
| bevacizumab biosimilar Drug Profile | 251 | 2 |
| bevacizumab biosimilar Drug Profile | 253 | 1 |
| bevacizumab biosimilar Drug Profile | 254 | 1 |
| bevacizumab biosimilar Drug Profile | 255 | 1 |
| bevacizumab biosimilar Drug Profile | 256 | 1 |
| bevacizumab biosimilar Drug Profile | 257 | 1 |
| bevacizumab biosimilar Drug Profile | 258 | 1 |
| bevacizumab biosimilar Drug Profile | 259 | 1 |
| bevacizumab biosimilar Drug Profile | 260 | 1 |
| BMS-936559 Drug Profile | 261 | 2 |
| BMS-986016 Drug Profile | 263 | 1 |
| BNC-105 Drug Profile | 264 | 5 |
| cabiralizumab Drug Profile | 269 | 4 |
| cabozantinib s-malate Drug Profile | 273 | 16 |
| capmatinib Drug Profile | 289 | 3 |
| Carboxyamidotriazole Orotate Drug Profile | 292 | 2 |
| carfilzomib Drug Profile | 294 | 12 |
| CB-1158 Drug Profile | 306 | 2 |
| CB-839 Drug Profile | 308 | 7 |
| CBL-0137 Drug Profile | 315 | 4 |
| CDX-014 Drug Profile | 319 | 1 |
| Cellular Immunotherapy for Cancer and Viral Infections Drug Profile | 320 | 1 |
| Cellular Immunotherapy for Metastatic Renal Cell Carcinoma Drug Profile | 321 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 322 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 323 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 324 | 1 |
| Cellular Immunotherapy to Inhibit PD-L1 for Oncology Drug Profile | 325 | 1 |
| Cellular Immunotherapy to Target CD70 for Oncology Drug Profile | 326 | 1 |
| Cellular Immunotherapy to Target MAGE-3, MAGE-4, Survivin, Her2 and COX-2 for Renal Cell Carcinoma Drug Profile | 327 | 1 |
| Cellular Immunotherapy to Target WT1 for Oncology Drug Profile | 328 | 1 |
| crizotinib Drug Profile | 329 | 7 |
| CS-2164 Drug Profile | 336 | 1 |
| CYP-0150 Drug Profile | 337 | 1 |
| dalantercept Drug Profile | 338 | 4 |
| DMS-612 Drug Profile | 342 | 1 |
| DSP-7888 Drug Profile | 343 | 1 |
| durvalumab Drug Profile | 344 | 11 |
| E-7046 Drug Profile | 355 | 1 |
| emibetuzumab Drug Profile | 356 | 2 |
| enadenotucirev Drug Profile | 358 | 4 |
| englerin A Drug Profile | 362 | 1 |
| enoblituzumab Drug Profile | 363 | 2 |
| entinostat Drug Profile | 365 | 7 |
| epacadostat Drug Profile | 372 | 5 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 377 | 8 |
| G-305 Drug Profile | 385 | 2 |
| GSK-3174998 Drug Profile | 387 | 1 |
| GW-6471 Drug Profile | 388 | 1 |
| Hex-hR1 Drug Profile | 389 | 1 |
| HKT-288 Drug Profile | 390 | 1 |
| HuATN-658 Drug Profile | 391 | 2 |
| ibrutinib Drug Profile | 393 | 26 |
| IMP-321 Drug Profile | 419 | 4 |
| INCAGN-1876 Drug Profile | 423 | 2 |
| INCB-50465 Drug Profile | 425 | 1 |
| interferon gamma-1b Drug Profile | 426 | 4 |
| Intuvax Drug Profile | 430 | 6 |
| ipilimumab Drug Profile | 436 | 9 |
| itacitinib adipate Drug Profile | 445 | 3 |
| ixazomib citrate Drug Profile | 448 | 9 |
| JNJ-64457107 Drug Profile | 457 | 2 |
| KAHR-101 Drug Profile | 459 | 1 |
| Kevetrin Drug Profile | 460 | 11 |
| KPT-251 Drug Profile | 471 | 1 |
| lenvatinib mesylate Drug Profile | 472 | 11 |
| LY-2510924 Drug Profile | 483 | 2 |
| MEDI-0680 Drug Profile | 485 | 1 |
| MethaSHELS Drug Profile | 486 | 1 |
| MGD-009 Drug Profile | 487 | 2 |
| MGN-1601 Drug Profile | 489 | 3 |
| mipsagargin Drug Profile | 492 | 5 |
| mirvetuximab soravtansine Drug Profile | 497 | 4 |
| MK-2206 Drug Profile | 501 | 3 |
| Monoclonal Antibodies to Inhibit CXCL1, CXCL7 and CXCL8 for Renal Cell Carcinoma Drug Profile | 504 | 1 |
| Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma Drug Profile | 505 | 1 |
| Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma Drug Profile | 506 | 1 |
| Monoclonal Antibody to Antagonize PD1 for Oncology Drug Profile | 507 | 1 |
| Monoclonal Antibody to Inhibit DLL4 for Oncology Drug Profile | 508 | 1 |
| Monoclonal Antibody to Target CAIX for Renal Cell Carcinoma and Solid Tumors Drug Profile | 509 | 1 |
| MP-0250 Drug Profile | 510 | 1 |
| NCE-001 Drug Profile | 511 | 1 |
| NEO-PV-01 Drug Profile | 512 | 2 |
| nintedanib Drug Profile | 514 | 9 |
| NIS-793 Drug Profile | 523 | 1 |
| nivolumab Drug Profile | 524 | 29 |
| NKTR-214 Drug Profile | 553 | 3 |
| ofranergene obadenovec Drug Profile | 556 | 6 |
| OMRCA-01 Drug Profile | 562 | 2 |
| Orellanine Drug Profile | 564 | 1 |
| pazopanib hydrochloride Drug Profile | 565 | 7 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 572 | 1 |
| pembrolizumab Drug Profile | 573 | 37 |
| pexastimogene devacirepvec Drug Profile | 610 | 8 |
| PF-04518600 Drug Profile | 618 | 1 |
| pidilizumab Drug Profile | 619 | 3 |
| PT-2385 Drug Profile | 622 | 2 |
| PT-2399 Drug Profile | 624 | 1 |
| radium Ra 223 dichloride Drug Profile | 625 | 9 |
| ramucirumab Drug Profile | 634 | 10 |
| Recombinant Protein for Oncology Drug Profile | 644 | 1 |
| Recombinant Protein to Agonize IFNAR1 and IFNAR2 for Oncology Drug Profile | 645 | 1 |
| regorafenib Drug Profile | 646 | 11 |
| rintatolimod Drug Profile | 657 | 9 |
| rocapuldencel-T Drug Profile | 666 | 7 |